Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P A Fasching

Showing results (101-110 of 109) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 109 results.
European Journal of Cancer (Oxford, England : 1990)|April 22, 2018
Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM studyN Nabieva, T Fehm, L Häberle, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patientsN Nabieva, S Kellner, T Fehm, et al.
Clinical Pharmacology and Therapeutics|September 25, 2013
CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populationsM A Province, M P Goetz, H Brauch, et al.
British Journal of Cancer|July 8, 2015
Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association ConsortiumC M Nagle, S C Dixon, A Jensen, et al.
British Journal of Cancer|October 29, 2014
Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium studyM Köbel, J Madore, S J Ramus, et al.
British Journal of Cancer|October 29, 2011
Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer riskK N Stevens, M Garcia-Closas, Z Fredericksen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 17, 2014
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†G von Minckwitz, S Loibl, M Untch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 31, 2020
Prognostic gene expression signature for high-grade serous ovarian cancerJ Millstein, T Budden, E L Goode, et al.
British Journal of Cancer|February 20, 2014
FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association ConsortiumD Agarwal, S Pineda, K Michailidou, et al.
Pageof 11

Showing results (101-110 of 109) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 109 results.
European Journal of Cancer (Oxford, England : 1990)|April 22, 2018
Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM studyN Nabieva, T Fehm, L Häberle, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patientsN Nabieva, S Kellner, T Fehm, et al.
Clinical Pharmacology and Therapeutics|September 25, 2013
CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populationsM A Province, M P Goetz, H Brauch, et al.
British Journal of Cancer|July 8, 2015
Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association ConsortiumC M Nagle, S C Dixon, A Jensen, et al.
British Journal of Cancer|October 29, 2014
Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium studyM Köbel, J Madore, S J Ramus, et al.
British Journal of Cancer|October 29, 2011
Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer riskK N Stevens, M Garcia-Closas, Z Fredericksen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 17, 2014
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†G von Minckwitz, S Loibl, M Untch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 31, 2020
Prognostic gene expression signature for high-grade serous ovarian cancerJ Millstein, T Budden, E L Goode, et al.
British Journal of Cancer|February 20, 2014
FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association ConsortiumD Agarwal, S Pineda, K Michailidou, et al.
Pageof 11